NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
Erasca, Inc.
NRG Oncology
CarThera
ITM Solucin GmbH
Eastern Cooperative Oncology Group
European Organisation for Research and Treatment of Cancer - EORTC